Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
Tarih
2021Yazar
Rietschel, P.
Pouliot, J.
Lee, S.
Seebach, F.
Lowy, I.
Gullo, G.
Bondarenko, I.
Sezer, A.
Kilickap, S.
GÜMÜŞ, MAHMUT
ÖZGÜROĞLU, Mustafa
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Mcginniss, J.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Makale [92796]